Evidence map›Paper›PMID 42357328›Full record

ReviewPharmaceutics2026

Advances in Camptothecin-Class Compounds Nanomedicines: A Comprehensive Review of Antitumor Strategies.

Mingliang Su, Zhiwei Liang, Long Chen, Taoyu Wang, Shabatula Aisika, Yanbin Peng, Yonghui Wu, Huahe Zhu, Lixin Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mingliang SuCollege of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730101, China.
Zhiwei LiangDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.ORCID 0009-0009-9182-995X
Long ChenSchool of Medicine, Tongji University, Shanghai 200092, China.
Taoyu WangYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
Shabatula AisikaDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
Yanbin PengDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
Yonghui WuDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
Huahe ZhuDepartment of Integrated Traditional Chinese and Western Medicine, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
Lixin WangCollege of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730101, China.

Funding

National Natural Science Foundation of China 82004115；82304968; 82374345Science and Technology Commission of Shanghai Municipality 18401901500,Shanghai Key Discipline of Traditional Chinese Medicine shzyyzdxk-2024106
6 · The paper itself

Abstract

Camptothecin-class compounds are anticancer active ingredients extracted from the Chinese unique medicinal plant, Camptotheca acuminata. They have been widely applied in the treatment of various cancers due to their high efficacy and broad-spectrum anti-cancer properties. This article summarizes the latest research progress over the past decade on various types of nanocarriers for camptothecin drugs. We discuss the nanodrug delivery systems for camptothecin compounds in four perspectives: passive targeting nanoparticles, active targeting nanoparticles, tumor microenvironment-responsive nanoparticles and exogenous stimulus-responsive nanoparticles. We also elaborate on the advantages of delivery nanoparticles, in vivo release characteristics and antitumor therapeutic effects. The purpose of this article is to provide a theoretical basis and innovative perspectives for the clinical application of the camptothecin drugs and the development of new pharmaceuticals.

Indexed as

camptothecin-class compoundsnanomedicine deliverytargeted deliverytumor microenvironment responsetumor treatment

Identifiers

PMID42357328
PMCPMC13306540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.